Boston Scientific Co. (NYSE:BSX) SVP Maulik Nanavaty sold 3,039 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $37.81, for a total value of $114,904.59. Following the completion of the sale, the senior vice president now directly owns 53,299 shares of the company’s stock, valued at $2,015,235.19. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Maulik Nanavaty also recently made the following trade(s):

  • On Friday, March 15th, Maulik Nanavaty sold 3,038 shares of Boston Scientific stock. The stock was sold at an average price of $40.11, for a total value of $121,854.18.
  • On Friday, February 15th, Maulik Nanavaty sold 3,039 shares of Boston Scientific stock. The stock was sold at an average price of $40.32, for a total value of $122,532.48.

Shares of Boston Scientific stock opened at $35.11 on Friday. Boston Scientific Co. has a 12 month low of $27.91 and a 12 month high of $41.00. The stock has a market cap of $50.29 billion, a P/E ratio of 23.88, a PEG ratio of 2.21 and a beta of 0.87. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.76 and a quick ratio of 0.54.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 6th. The medical equipment provider reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.02. Boston Scientific had a return on equity of 25.92% and a net margin of 17.01%. The company had revenue of $2.56 billion during the quarter, compared to analysts’ expectations of $2.57 billion. During the same period last year, the business posted $0.34 EPS. Boston Scientific’s revenue for the quarter was up 6.4% on a year-over-year basis. As a group, equities analysts expect that Boston Scientific Co. will post 1.55 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. 1832 Asset Management L.P. boosted its holdings in Boston Scientific by 187.2% during the 4th quarter. 1832 Asset Management L.P. now owns 1,240,550 shares of the medical equipment provider’s stock valued at $43,836,000 after acquiring an additional 808,650 shares during the period. IFM Investors Pty Ltd boosted its holdings in Boston Scientific by 12.9% during the 1st quarter. IFM Investors Pty Ltd now owns 90,005 shares of the medical equipment provider’s stock valued at $3,454,000 after acquiring an additional 10,276 shares during the period. Amundi Pioneer Asset Management Inc. boosted its holdings in Boston Scientific by 26.1% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 3,727,580 shares of the medical equipment provider’s stock valued at $131,734,000 after acquiring an additional 770,542 shares during the period. Insight Wealth Strategies LLC purchased a new position in Boston Scientific during the 4th quarter valued at about $882,000. Finally, Kovack Advisors Inc. purchased a new position in Boston Scientific during the 4th quarter valued at about $220,000. Institutional investors own 91.70% of the company’s stock.

A number of analysts have issued reports on BSX shares. Canaccord Genuity cut their target price on Boston Scientific from $45.00 to $43.00 and set a “buy” rating for the company in a research note on Wednesday. Argus raised their target price on Boston Scientific from $43.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, February 13th. SunTrust Banks reaffirmed a “buy” rating and issued a $47.00 target price on shares of Boston Scientific in a research note on Friday, February 8th. Guggenheim reaffirmed a “buy” rating and issued a $48.00 target price on shares of Boston Scientific in a research note on Friday, February 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $43.00 price target on shares of Boston Scientific in a report on Wednesday, February 6th. Three research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $40.72.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/boston-scientific-co-bsx-svp-sells-114904-59-in-stock/2973634.html.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

See Also: What is the S&P 500 Index?

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.